This afternoon, a panel at the BIO Convention is entitled, "Translational Research Forum: From Bench to Bedside in a Bioeconomy- Government, Industry, and University Models to Catalyze Economic Growth and Patient Access," It will discuss how research partnerships with other research entities can help speed the pace at which discoveries become better health outcomes.
On that note, here is some background on the rich history and tradition that Lilly has in partnering with other actors to produce innovative medicines for patients. In 1923, Lilly partnered with the University of Toronto to produce Insulin. Within a year, enough insulin was produced to supply the entire North American continent. Sixty years later, in 1982, a partnership with Genentech resulted in the first production of biosynthetic human insulin, which once again made vital treatment more accessible to patients.
Today, Lilly continues its tradition in new models of collaboration that seek to improve health worldwide.
- The Lilly MDR-TB Partnership is working to reduce the burden of multi-drug resistant tuberculosis.
- In effort to reduce the prevalence of non-communicable diseases, specifically diabetes, Lilly created the Lilly NCD Partnership.
Additionally, Lilly has begun collaboration with the National Institutes of Health on two new initiatives:
- An innovative initiative, the Phenotypic Drug Discovery (PD²), provides pro bono analysis of compounds submitted by outside investigators.
- A partnership with the NIH National Center for Translational Science (NCATS), connects researchers with industry-developed molecules and data to discover new therapeutic uses for existing molecules.
There is no substitute for the power of effective partnership. That's why Lilly is building active private-public partnerships to improve health in areas where we have deep expertise, knowledge, and capabilities.